http://www.lsis.com/goto/r105/rss 2010-06-23T11:11:04+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FB%1C%7Exz A specific substrate to Mu class glutathione S-transferase (GST), 1,2-dichloro-4-nitrobenzene (DCNB), was administered to mice with a disrupted GST Mu 1 gene (Gstm1-null mice) to investigate the in vivo role of murine Gstm1 in toxicological responses to DCNB. A single oral administration of DCNB at doses of 500 and 1000 mg/kg demonstrated a marked increase in blood methemoglobin (MetHB) in Gstm1-null mice, but not in wild-type mice. Therefore, Gstm1-null mice were considered to be more predisposed to methemoglobinemia induced by a single dosing of DCNB. In contrast, 14-day repeated dose studies of DCNB at doses up to 600 mg/kg demonstrated a marked increase in blood MetHB in both wild-type (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FB%12zxz A-503083 B, a capuramycin-type antibiotic, contains an L-aminocaprolactam and an unsaturated hexuronic acid that are linked via an amide bond. A putative class C beta-lactamase (CapW) was identified within the biosynthetic gene cluster that-in contrast to the expected beta-lactamase activity-catalyzed an amide-ester exchange reaction to eliminate the L-aminocaprolactam with concomitant generation of a small but significant amount of the glyceryl ester derivative of A-503083 B, suggesting a potential role for an ester intermediate in the biosynthesis of capuramycins. A carboxyl methyltransferase, CapS, was subsequently demonstrated to function as an S-adenosylmethionine-dependent carboxyl (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FB%11u%7D%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97f%FB%11t%7Ex SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FB%11z%7C%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FC%10x%7Cs Plasma levels of valproic acid (VPA) are decreased by the concomitant use with carbapenem antibiotics, such as panipenem (PAPM). One of the plausible mechanisms of this interaction is the inhibition of VPA glucuronide (VPA-G) hydrolysis by carbapenems in the liver. In order to elucidate this interaction mechanism, we purified VPA-G hydrolase from human liver cytosol, in which the hydrolytic activity was mainly located. After a chromatographical purification, the VPA-G hydrolase was identified as acylpeptide hydrolase (APEH). APEH depleted cytosol, prepared by an immunodepletion method, completely lacked the hydrolytic activity. These results demonstrate that APEH is a single enzyme (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FC%14%7F%7E%7D Calibration models for nondestructive NIR analysis of API (active pharmaceutical ingredient) contents in two separate layers of intact bilayer tablets were established. These models will enable the use of NIR transmittance spectroscopy in bilayer tableting processes for the control of API contents in separate layers. Acetaminophen and caffeine anhydrate were used as APIs, and tablets were made by the direct compression method. Their NIR spectra were measured in the transmittance mode. The reference assay was performed by HPLC. Calibration models were generated by the partial least-squares (PLS) regression. The initial calibration generated models with insufficient linearity and accuracy (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FD%12x%7C%7E With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discovery of prodrug 15c, which strongly inhibited glucose production in monkey hepatocytes. Furthermore, prodrug 15c lowered blood glucose levels in fasted cynomolgus monkeys. |-| Bioorg Med Chem. |-| Tsukada T, Kanno O, Yamane T, Tanaka J, Yoshida T, Okuno A, Shiiki T, Takahashi M, Nishi T. |-| Medicinal Chemistry Research Laboratories I, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FD%11%7F%7Es DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/86b7d0/opportunities_in_e) has announced the addition of the "Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas" report to their offering. Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas Pharmaceuticals, Generics, Vaccines, OTCs, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners. This report provides market (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FD%11%7Ez%7F WASHINGTON-(BUSINESS WIRE)-SAS Drug Development has long enabled organizations to focus resources on efficiently developing drugs rather than building complex clinical technology infrastructures. Now, this mature, powerful solution from SAS, the leader in business analytics, features a host of innovations and enhancements that include an integrated workflow system to automate development processes and an improved SAS programming environment designed for seasoned SAS experts. After working closely with SAS and reviewing early versions, it s clear that SAS truly listened to its customers and understands the value of partnering with the industry, getting value from users involved daily in (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97f%FD%15%7Cx%7C NEW YORK - The U.S. Food and Drug Administration is looking into whether Daiichi Sankyo's blood pressure medicine Benicar increases the risk of heart-related death, although the agency said it still believes the benefits of the drug outweigh its potential risks. The FDA said it is evaluating data from a pair of clinical trials in which diabetes patients taking the drug, known chemically as olmesartan, had a higher rate of death from heart related causes compared with patients taking a placebo. In a safety notice posted Friday, the agency cautioned that it has not concluded that Benicar increases the risk of death, and Daiichi has expressed its confidence in the drug. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FE%1Cu%7F%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company s president and chief executive officer, will present at the Goldman Sachs 31st Annual Global Healthcare Conference at 1:20 p.m. PDT / 4:20 p.m. EDT on Tuesday June 15, 2010 in Los Angeles. Dr. Scangos will discuss the company s corporate strategy and development pipeline, and provide a general business update. The event will be webcast and may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FE%1Cyz%7B The primary objective of this study was to assess the effect of a standard high-fat meal on the single-dose (60 mg) pharmacokinetics (PK) of edoxaban in healthy Japanese and Caucasian male volunteers matched by body mass index. This was an open-label, randomized, 2-period crossover study. All 32 enrolled volunteers completed the study per protocol. Both serial blood and urine samples were collected, and edoxaban concentrations were analyzed by a validated liquid chromatography/tandem mass spectrometry method. Activated partial thromboplastin and prothrombin times were obtained as measures of pharmacodynamic effect. The point estimates of the geometric mean ratios (fed/fasted) for AUC0-t, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FE%15x%7E%7F TRENTON, N.J.-(BUSINESS WIRE)-BioNJ, New Jersey s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis US and Defined Health. This is a significant opportunity for New Jersey s biotechnology firms to network with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%12%7Dxy SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that Michael M. Morrissey, PhD, the company s president of research and development, will present at Jefferies 2010 Global Life Sciences Conference at 10:00 a.m. EDT / 7:00 a.m. PDT on Wednesday June 9, 2010 in New York. Mr. Morrissey will discuss the company s corporate strategy, development pipeline, and provide a general business update. The event will be webcast and may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%12%7Dz%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway also has been implicated as a mediator of resistance to agents targeting epidermal growth factor receptor (EGFR) family members. The presentations will be made at the 2010 Annual Meeting of the American Society of Clinical Oncology, which is being held June 4-8 in Chicago. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97f%FF%12%7D%7Fx WOBURN, Mass. & TOKYO-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer. text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%13tw%7D SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq: EXEL) today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway also has been implicated as a mediator of resistance to agents targeting epidermal growth factor receptor (EGFR) family members. The presentations will be made at the 2010 Annual Meeting of the American Society of Clinical Oncology, which is being held June 4-8 in Chicago. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%13tx%7E CHICAGO-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today reported data on Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients retreated with single-agent brentuximab vedotin (SGN-35). Preliminary data demonstrate that objective responses were achieved in seven out of 11 retreatment experiences and that brentuximab vedotin was well-tolerated in the retreatment setting. The data were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois. Through our broad ongoing clinical (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%13t%7Bx WOBURN, Mass. & TOKYO-(BUSINESS WIRE)-ArQule, Inc. (NASDAQ: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer. The full set of data will now help guide planning for next-stage clinical development activities, as well as discussions with regulatory authorities. One hundred sixty-seven patients participated in this Phase 2, double-blind, randomized, signal generation trial. All patients (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FF%13%7C%7E%7E CC chemokine receptor 4 (CCR4) is generally recognized as a preferential marker for T helper 2 cells, and we have previously reported morpholine-derivative CCR4 antagonists, RS-1154 and RS-1269. Here, we investigate the pharmacological profiles of a novel pyrimidine-derivative CCR4 antagonist, 2-{4-[2-(diethylamino)ethoxy]phenyl}-N-(2,4-difluorobenzyl)-5-fluoropyrimidin-4-amine (RS-1748), which showed potency to inhibit the bindings of [(125)I]CCL17 and [(35)S]GTPgammaS to human CCR4-expressing Chinese hamster ovary (CHO) cells with IC(50) values of 59.9 nM and 18.4 nM, respectively. Furthermore, RS-1748 inhibited ovalbumin-induced airway inflammation in guinea pigs at a dose of 10 mg/kg. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97f%FF%10z%7D%7F CS-758 was selected as a candidate for clinical trials, but since its water-solubility was insufficient for an injectable formulation, phosphoryl ester prodrugs were designed. In this study, the synthesis and evaluation of these injectable prodrugs are described. Phosphoryl ester 17h was soluble in water, and was stable in both water and in a solid state. 17h was converted to CS-758 in human liver microsome and was also converted to CS-758 in rats after intravenous (i.v.) administration with good conversion speed and efficiency. 17h (i.v.) reduced the viable cell counts in kidneys in a murine hematogenous Candida albicans infection model and in lungs in a murine pulmonary Aspergillus (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%15u%7E%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that it will hold two investor briefings in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting from 6:30 p.m. to 8:00 p.m. CDT on Saturday, June 5, 2010 and 6:00 p.m. to 7:30 p.m. CDT on Monday, June 7, 2010. The events will be available via conference call and webcast. Access numbers for the events are as follows: Saturday June 5, 2010 dial: 1-800-510-9691 (domestic) and +1-617-614-3453 (international); the participant passcode is: 44562547. Monday June 7, 2010 dial: 1-866-783-2144 (domestic) and +1-857-350-1603 (international); the participant passcode is: 72899846. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97f%FF%15tv%7B DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/f8bc26/option_and_evaluat) has announced the addition of the "Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition" report to their offering. Option and Evaluation Agreements in Pharma and Biotech, 2nd Edition The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97g%F6%12%7B%7B%7C SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has entered into agreements providing for two separate financing transactions with Silicon Valley Bank and Deerfield Management for an aggregate of $160.0 million in capital. Exelixis expects to use the proceeds from these transactions to finance the repayment of the remaining obligations under its loan from GlaxoSmithKline and to fund development activities related to its lead compound XL184. The blended cost of capital for both transactions is expected to remain under 10%. The transaction with Silicon Valley Bank is an extension of the company s existing credit facility with the bank and provides for a (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F6%12%7Fxr BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that Clay B. Siegall, Ph.D., President and Chief Executive Officer, will present a company overview at three upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics website, www.seattlegenetics.com, under the œInvestor and News  section. Jefferies 2010 Global Life Sciences ConferenceTuesday, June 8, 20101:00 p.m. Eastern TimeNew York, NY 9th Annual Needham Healthcare ConferenceWednesday, June 9, 20108:40 a.m. Eastern TimeNew York, NY 31st Annual Goldman Sachs Healthcare ConferenceTuesday, June 15, 20103:05 p.m. Pacific TimeLos Angeles, CA (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%F7%13%7D%7D%7D ARQ-197 is an oral, selective c-Met inhibitor under development by ArQule Inc, in partnership with Daiichi Sankyo Co Ltd and Asian licensee Kyowa Hakko Kirin Co Ltd, for the potential treatment of solid tumors, including NSCLC, hepatocellular carcinoma and pancreatic cancer, as well as microphthalmia transcription factor-driven tumors. c-Met, a key cell surface receptor tyrosine kinase involved in diverse regulatory functions, is often aberrantly activated in human cancers. While the precise mechanism of action of ARQ-197 remains undefined, data from preclinical studies have demonstrated that ARQ-197 inhibits c-Met activation in numerous human tumor cell lines and specifically targets (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F7%10%7E%7B%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/52bee2/managed_care_pull) has announced the addition of the "Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share" report to their offering. Managed Care Pull - Through Excellence: From Formulary Access to Increased Market Share Winning a favorable managed care formulary position can be a Herculean task for pharmaceutical companies today, but successful brand leaders know that position alone doesnt guarantee increased market share. Savvy brand leaders develop and carry out extensive pull-through programs to drive product sales after a formulary win. The analyst (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%F7%11%7B%7Er AIM: The genesis of abdominal aortic aneurysms is associated with remodeling of the vascular wall by angiogenesis as well as proteolysis. Vascular endothelial growth factor (VEGF) is known to be a regulator of angiogenesis and to simultaneously stimulate elastolytic proteinases. We analyzed the expression and localization of VEGF in human abdominal aortic aneurysms compared to normal human aorta METHODS: Eighteen infrarenal aortic aneurysm samples were collected at the time of abdominal aortic aneurysm surgery, while nine normal aortic samples were obtained from autopsy specimens. Immunohistochemical staining was performed to detect VEGF. Immunoenzyme or immunofluorescent double staining (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97g%F8%1D%7Cxz SOUTH SAN FRANCISCO, Calif.- Exelixis, Inc. (Nasdaq:EXEL) cordially invites you to attend two investor receptions in conjunction with the 2010 ASCO Annual Meeting: ¢ Saturday, June 5, 2010 - "XL184: Phase 2 GBM study results and development update" ¢ Monday, June 7, 2010 - "Highlights from XL184 ASCO presentations: Phase 2 randomized discontinuation trial (RDT), long term follow-up on MTC Phase 1 trial, and Phase 1b NSCLC trial" Both receptions will be held in the Honore Ballroom at the Palmer House Hilton Hotel, 17 East Monroe Street, Chicago, IL 60603 at 6:00 p.m. CT. Please RSVP by visiting the following link: http:/www.exelixis.com/form_asco_2010_investor.shtml About Exelixis (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v105/%3B%97g%F8%12tzs The Harvard Clinical Research Institute (HCRI) announced that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study. Enrollment is opening at multiple centers across the EU and will include participation in the following countries: the Czech Republic, France, Germany, Hungary, Poland, Romania and the United Kingdom. Enrollment into the DAPT Study was initiated in the United States in October 2009. The DAPT Study is a four-year clinical trial investigating the duration of dual antiplatelet therapy (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F8%12zv%7C BOSTON-(BUSINESS WIRE)-The Harvard Clinical Research Institute (HCRI) announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study. Enrollment is opening at multiple centers across the EU and will include participation in the following countries: the Czech Republic, France, Germany, Hungary, Poland, Romania and the United Kingdom. Enrollment into the DAPT Study was initiated in the United States in October 2009. The DAPT Study addresses a critical gap in current scientific evidence (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F8%12zz%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8e8b65/cardiovascular_dru) has announced the addition of the "Cardiovascular Drugs - Global Strategic Business Report" report to their offering. Cardiovascular Drugs - Global Strategic Business Report This report analyzes the worldwide markets for Cardiovascular Drugs in US$ Million. Cardiovascular diseases can be prevented or treated using different classes of drugs. Broadly, the major classes of cardiovascular drugs include: ACE Inhibitors, Angiotensin II Receptor Blockers, Antiarrhythmics, Antithrombotics, Beta Blockers,. Calcium Channel Blockers, Antihyperlipidemics, and Others. The report (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%F8%13%7Bz%7F Liver X receptors (LXRs), LXRalpha and LXRbeta, are members of the nuclear receptor superfamily and regulate the expression of genes involved in the regulation of cholesterol and fatty acid metabolism. Human plasma, unlike mouse plasma, contains cholesteryl ester transfer protein (CETP), which plays an important role in reverse cholesterol transport (RCT). LXRs induce CETP transcription via a direct repeat 4 element in the CETP promoter. However, the specific roles of the individual LXR subtypes in CETP expression and their consequences on plasma lipoprotein metabolism are still unclear. Here we showed that synthetic LXR agonist enhanced plasma CETP activity and resulted in non-high (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%F8%16%7D%7Fz Side population (SP) assay composed of Hoechst 33342 staining and subsequent flow cytometric analysis has been widely utilized for characterizing putative cancer stem cells (CSCs) in various human malignancies. The present study was designed to evaluate the SP assay as a research tool for mesothelial CSCs. A distinct fraction of SP cells was identified in various human malignant mesothelioma (HMM) cell lines, ranging from 0.05 to 1.32%. The sorted mesothelial SP cells exhibited enhanced proliferation potentials and higher expression of stem-cell genes, compared to non-SP (NSP) cells. Cisplatin treatment increased percentage of SP cells in the HMM cell lines. However, tumorigenic potential (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97g%F8%17zxs Antitope Ltd. ("Antitope") today announced a research collaboration with the Japanese multinational pharmaceutical company Daiichi Sankyo Company Limited ("Daiichi Sankyo") in which Antitope will apply its proprietary EpiScreen ¢ technology to analyze the immunogenicity of Daiichi Sankyo s therapeutic monoclonal antibodies. "We are very pleased to be working with Daiichi Sankyo whom we recognize as a world leader for development and commercialization of therapeutic antibodies," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope. "We look forward to assisting Daiichi Sankyo in selecting antibodies with low immunogenicity potential arising from their pioneering R&D (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F8%17%7Fz%7B BOTHELL, Wash. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, which is highly expressed on ALCL cells. Brentuximab vedotin has the potential to provide an improvement in patient care, which is our primary goal, and is another step toward global oncology leadership for Millennium. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F8%17%7Ew%7F BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the appointment of Charles (Chip) R. Romp as Vice President, Sales. Mr. Romp brings more than 19 years of biotechnology and pharmaceutical sales and sales management experience to the company, most recently from Genentech, a wholly owned member of the Roche Group. In addition, the company announced the promotion of Jonathan Drachman, M.D., to Senior Vice President, Research and Translational Medicine. As we move towards planned submission of our New Drug Application for brentuximab vedotin (SGN-35) in the first half of 2011, we will be strongly positioned given Chip s deep understanding of new product (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v105/%3B%97g%F8%17%7Czs ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and co-development partner BioInvent will receive a milestone payment of EUR10 million from Roche under the terms of the strategic alliance agreement signed in June 2008. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of all revenue from the alliance with Roche for this anti-cancer antibody. This trial is a multi-centre, open-label (monotherapy), (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7Dx%7B SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) today reported interim data from an ongoing Phase 1b/2 study of XL184 in patients with non-small cell lung cancer (NSCLC). Dr. Heather Wakelee from Stanford University School of Medicine in Stanford, CA will present the data in a poster discussion session (Abstract #3017) on Sunday, June 6 at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. The evidence of clinical activity, particularly in refractory NSCLC patients previously treated with erlotinib or with drug-resistant EGFR mutations and/or MET copy number gain is of particular note, given the poor prognoses that these patients (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7D%7Br WOBURN, Mass.-(BUSINESS WIRE)-ArQule, Inc. (Nasdaq: ARQL) today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.  Clinical Science Symposium Oral presentation #LBA7502: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The symposium will take (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7Dz%7D BOTHELL, Wash.-(BUSINESS WIRE)-Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois. The presentation will highlight data from Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL) patients who have been retreated upon relapse after discontinuing previous brentuximab vedotin therapy. Objective responses with brentuximab vedotin (SGN-35) retreatment in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7D%7E%7B SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) today reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma (GB), the most common and aggressive form of brain cancer. Dr. Patrick Wen from the Dana Farber Cancer Institute in Boston, MA will present the data in an Oral Session (Abstract #2006) on Saturday, June 5 at 5:00 p.m. at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. We are encouraged by the clinical activity, tolerability and safety profile of XL184 at the 125 mg dose in recurrent GB The phase 2 study is evaluating the safety, tolerability, and clinical activity of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7Cwr SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) today reported long-term results in a cohort of 37 medullary thyroid cancer (MTC) patients who participated in the phase 1 study of XL184. Dr. Razelle Kurzrock from the MD Anderson Cancer Center in Houston, TX will present the data in a Clinical Science Symposium (Abstract #5502) on Monday, June 7 at 10:15 AM at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. These long-term data demonstrate that XL184 provides clinical benefit to patients with medullary thyroid cancer, and support the ongoing phase 3 pivotal trial of XL184 in this indication Thirty-seven of the 85 patients enrolled (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%F9%1D%7Cv%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) today reported interim data from an ongoing adaptive randomized discontinuation trial (RDT) of single agent XL184 in patients with melanoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), pancreatic, gastric/GE junctional, prostate, ovarian, or breast cancer who have measurable disease and had undergone up to 3 prior lines of systemic therapy. Dr. Michael Gordon from Premier Oncology of Arizona in Scottsdale, AZ will present the data in the Trials in Progress Session (Abstract #TPS188) on Monday June 7 at the 2010 Annual Meeting of the American Society of Clinical (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v105/%3B%97g%F9%17twr SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ:EXEL) today reported interim data from an ongoing Phase 1b/2 study of XL184 in patients with non-small cell lung cancer (NSCLC). Dr. Heather Wakelee from Stanford University School of Medicine in Stanford, CA will present the data in a poster discussion session (Abstract #3017) on Sunday, June 6 at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago. XL184 is a potent inhibitor of MET, a kinase which plays important roles in the proliferation, migration, and survival of cancer cells. Recent evidence indicates a key role for MET in NSCLC cells that are dependent on EGFR signaling, with (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%F9%15yy%7F Aims: Despite improvements achieved in laboratory medicine over the years, discrepant results from different clinical laboratories are still a source of imminent risk to patients and the pharmaceutical industry. The problem is aggravated by a disconnection between laboratorians and clinicians or drug developers. Materials & methods: In this report, results from proficiency testing, originally established as a tool for good laboratory practice, were used to highlight the size of the problem and its impact on patients and pharmaceutical trials. Results from three laboratory tests, believed to be standardized and commonly requested as tools in the management of patients, and decision-making (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v105/%3B%97g%FA%12xvy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/8fac3e/acute_coronary_syn) has announced the addition of the "Acute Coronary Syndrome - Global Strategic Business Report" report to their offering. Acute Coronary Syndrome - Global Strategic Business Report This report analyzes the global market for Acute Coronary Syndrome Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 60 companies including Abbott Laboratories Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddys Laboratories Ltd., Eli Lilly and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v105/%3B%97g%FA%10%7Fx%7F Phenotypic plasticity of T helper 17 (Th17) cells suggests instability of chromatin structure of key genes of this lineage. We identified epigenetic modifications across the clustered Il17a and Il17f and the Ifng loci before and after differential IL-12 or TGF-beta cytokine signaling, which induce divergent fates of Th17 cell precursors. We found that Th17 cell precursors had substantial remodeling of the Ifng locus, but underwent critical additional modifications to enable high expression when stimulated by IL-12. Permissive modifications across the Il17a-Il17f locus were amplified by TGF-beta signaling in Th17 cells, but were rapidly reversed downstream of IL-12-induced silencing of the (…)